Biologic therapies are revolutionising severe asthma management, showcasing potential for remission, but cost and equitable access are the major barriers, according to a report on Tuesday.
Biologic
therapy, also known as immunotherapy, is a type of treatment that uses
substances derived from living organisms to treat disease.
The
report by GlobalData, a data and analytics company, showed that the new
Biologics target specific inflammatory pathways, shifting care from symptom
control to potential remission.
Biologic
treatments like dupilumab interleukin-4 receptor alpha and tezepelumab
(anti-thymic stromal lymphopoietin (TSLP)) show potential for wider
application. They also offer benefits to patients with various inflammatory
profiles.
As per
real-world evidence, these therapies have proved their efficacy across diverse
patient profiles, including those with complex asthma cases.
However,
the report cited barriers such as cost and accessibility. It stressed the
urgent need for equitable healthcare solutions to ensure the widespread
adoption of these transformative treatments.
“Biologics
have fundamentally changed our approach to severe asthma by enabling targeted,
personalised treatment, but expanding access is crucial to realising their full
potential,” Sravani Meka, Senior Pharmaceutical Analyst at GlobalData.
“The
long-term impact of these therapies could shift asthma management from simply
controlling symptoms to achieving remission, like advances seen in fields like
rheumatoid arthritis,” Meka added.
While
biologics have shown great promise, barriers such as cost, access, and
insurance coverage limit their availability, particularly in underserved
communities.
This
is further complicated by environmental and social factors. Many patients in
high-risk areas are disproportionately exposed to pollutants that worsen
symptoms.
“Tezepelumab’s
broad efficacy, even for patients with low eosinophil (a type of white blood
cell that helps fight infections) counts, highlights the potential of biologics
to address asthma across diverse profiles and patient demographics,” Meka said.
Systemic
changes to improve healthcare equity and accessibility are crucial even as
efforts to expand access to biologics in severe asthma treatment are underway,
Meka
called for “sustained attention to cost and accessibility issues”. She noted
that this will ensure that biologics are available to all needy patients.
No comments:
Post a Comment